New vision tests could speed up AMD treatment trials
NCT ID NCT07515521
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing new eye exams to see if they can better track early age-related macular degeneration (AMD). Researchers will measure how quickly the eye adapts to darkness in 150 healthy volunteers and people with early AMD. The goal is to find reliable ways to measure disease progression, which could help design future treatment trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide better ways to measure early AMD progression, enabling more effective treatment trials in the future.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly help patients. The tests may not prove sensitive enough to track disease changes over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Ophthalmology, University Hospital Bonn
RECRUITINGBonn, 53127, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can At-Home eye scans personalize wet AMD treatment?
- AI eye doctor: could a computer spot Blindness-Causing diseases faster than humans?
- Gene therapy injection aims to halt blinding eye disease
- Scientists track Long-Term safety of experimental AMD therapy
- AMD Patients' knowledge gaps revealed in new study
- Cheaper eye drug could save millions in AMD treatment costs